Belmont, CA, United States of America

Michael J Weickert


Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 95(Granted Patents)


Company Filing History:


Years Active: 2002-2006

Loading Chart...
2 patents (USPTO):

Title: Innovations by Michael J. Weickert: Pioneering Advances in Hemoglobin Research

Introduction: Michael J. Weickert is a prominent inventor based in Belmont, CA, who has made significant contributions to the field of biotechnology through his innovative research in hemoglobin mutants. With a total of two patents, his work focuses on enhancing the properties of recombinant hemoglobins for various applications.

Latest Patents: Michael's most recent patents pertain to "Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging." These inventions relate to novel recombinant hemoglobins designed to exhibit reduced nitric oxide scavenging, alongside an increased capacity for soluble expression. Furthermore, his patents outline methods for boosting the soluble expression of recombinant hemoglobin by incorporating exogenous hemin in molar excess relative to the heme binding sites of the recombinant hemoglobin.

Career Highlights: Throughout his career, Michael has been associated with Baxter Biotech Technology Sarl, where he has been able to leverage his expertise in biotechnology and hemoglobin research. His inventive work has not only contributed to his personal achievements but has also pushed the boundaries of what is possible in the field.

Collaborations: In his professional journey, Michael has had the opportunity to collaborate with notable colleagues such as Christopher B. Glascock and Antony James Mathews. These partnerships have likely enriched his research and innovation, fostering an environment conducive to groundbreaking scientific advancements.

Conclusion: Michael J. Weickert's contributions to hemoglobin research highlight his role as an innovator in the biotechnology sector. His patents reveal a dedication to enhancing the functionality of recombinant hemoglobins, showcasing the potential for improved therapeutic applications. Through collaboration and a commitment to innovation, Michael continues to make a lasting impact in his field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…